secretagogue

Repaglinide (AG-EE 623ZW) 是一种能够用于2 型糖尿病的胰岛素促分泌剂。

L-692429 (MK-0751) 是一种有效的非肽基生长激素促分泌素 (GHS) 激动剂，是一种苯并内酰胺的衍生物，可逆转糖皮质激素对 GH 分泌的抑制。L-692429 对 G 蛋白偶联受体 (G protein-coupled receptor)具有很高的亲和力，可用于研究肢端肥大症和肥胖。

Anamorelin (ONO-7643) 是新型ghrelin receptor 激动剂，根据FLIPR 检测，得到其EC50=0.74 nM。

Ibutamoren Mesylate (MK-0677) 是非肽段类生长激素促分泌素受体 (GHSR) 激动剂，也是一种口服有活性的生长激素 (GH) 促分泌素。

PF-5190457 是具有选择性的、有效的生长素释放肽受体选择性的反向激动剂(pKi:8.36)。

TC-G-1008 (GPR39-C3) 是一种口服有活性的 GPR39激动剂，可作用于大鼠受体(EC50: 0.4 nM)和人类受体(EC50:0.8 nM)的。

AnaMorelin hydrochloride (RC-1291 hydrochloride) 是生长素受体激动剂，根据 FLIPR 检测，得到 EC50=0.74 nM。

Capromorelin Tartrate (CP 424391-18) 是口服有活性的 growth hormone secretagogue receptor 有效激动剂，能够作用于 hGHS-R1a(Ki:7 nM)。

Relamorelin(BIM28131, RM131) 是一种具有选择性和有效性的生长素释放肽 生长激素促分泌素受体 (GHSR) 激动剂，对 GHS-1a 受体具有很高的亲和力（Ki值为0.42 ± 0.063 nM）。Relamorelin(BIM28131, RM131) 也是一种具有中枢渗透性的五肽类似物，可增加生长激素水平，加速胃排空，具有研究恶病质的潜力。

JMV 2959 hydrochloride (925238-89-7 free base) 是一种生长激素促分泌素受体 1a 型 (GHS-R1a) 拮抗剂，在 LLC-PK1 细胞中的 IC50 为 32±3 nM。

JMV 2959 is an antagonist of growth hormone secretagogue receptor type 1a (GHS-R1a) (IC50: 32 nM).

TM-N1324 是一种 GPR39 激动剂。 TM-N1324 在没有和存在 Zn2+ 的情况下分别以 280 nM 和 9 nM 的高效率和效力激活人 GPR39。 TM-N1324 对鼠 GPR39 表现出相似的效力，EC50 分别为 180 nM 和 5 nM。

Repaglinide D5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for treatment type-2 diabetes mellitus.

Ibutamoren (MK-677) 是一种药物，可作为一种有效的、口服活性的生长激素促分泌素，模仿内源性激素 ghrelin 的 GH 刺激作用。它还改变了身体脂肪的代谢，因此可能在肥胖症的治疗中具有应用。

Arylquin 1 是一种前列腺-凋亡-反应-4(Par-4)促分泌剂，靶向波形蛋白诱导 Par-4 分泌。Arylquin 1 通过诱导溶酶体膜通透性 (LMP) 诱导癌细胞非凋亡性细胞死亡。

Capromorelin, a member of the growth hormone secretagogue (GHS) class of drugs, is a ghrelin receptor agonist and a novel therapy for stimulation of appetite in dogs with Ki value of 7 nM for hGHS-R1a and EC50 value of 3 nM for rat pituicyte. Capromorelin

PF-04628935 is a potent antagonist inverse agonist of the ghrelin receptor, growth hormone secretagogue receptor 1a (GHS-R1a) with an IC50 of 4.6 nM. PF-04628935 is orally bioavailable and brain penetrant.

SM-130,686 is a potent, orally-active agonist of the ghrelin growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue. It has around half the potency of the endogenous agonist ghrelin as a stimulator of growth hormone release.

BMS-317180 is a potent, novel, orally effective growth hormone secretagogue (GHS) that shows an excellent safety profile in preclinical studies. The compound was advanced into clinical development.

EX-1314 (BMS-604992) is a growth hormone secretagogue receptor (GHSR) agonist.

L 163255 is a type of growth hormone secretagogue (GHS).

L-739943 is a growth hormone secretagogue.

Ghrelin is an endogenous ligand for the growth hormone secretagogue receptor that stimulates food intake and transduces signals to hypothalamic regulatory nuclei that control energy homeostasis. JMV3002 is a potent ghrelin receptor antagonist with an IC50 value of 1.1 nM in vitro. At 80 μg kg, JMV3002 inhibits hexarelin-stimulated food intake by as much as 98% in rats. JMV3002 alone does not elicit growth hormone release nor does it inhibit hexarelin-stimulated growth hormone secretion when tested in infant rats at a dose of 160 μg kg.

AZ-GHS-22 is an inverse agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), which is also known as the ghrelin receptor.1It binds to GHS-R1a with an IC50value of 0.77 nM. AZ-GHS-22 decreases food intake in mice by 54% in the first two hours after administration of a 100 mg/kg dose. 1.McCoull, W., Barton, P., Brown, A.J.H., et al.Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonistsJ. Med. Chem.57(14)6128-6140(2014)